Pfizer Inc chief executive Ian Read on Tuesday said that the company would not change its philosophy on pricing of its medicines or when it takes price increases, bucking a trend by some rivals of the largest US drugmaker.
The comments, made on a conference call after Pfizer reported slightly lower than expected fourth-quarter profit, came as several of Read’s industry peers met with US President Donald Trump, who has insisted prescription drug prices must come down.
Discussions with Trump included some ideas on how that goal might be accomplished, including tax reform and undoing regulations that slow entry of new drugs and generics to the market.
Photo: Reuters
Three large drugmakers, including US-based AbbVie Inc and Allergan, have already vowed to keep price increases this year under 10 percent.
AbbVie and Allergan also pledged to take one round of increases, rather than the common industry standard of twice-yearly price hikes.
“I believe we have always priced responsibly, so I don’t need to make that commitment,” Read said in a telephone interview.
“We feel we appropriately price our products to the value in the marketplace and that’s essential for free-market systems where you need to recover and direct resources to further innovation,” he said.
Drugmakers have faced intense criticism from politicians, insurance companies and patient advocacy groups over costs of new medicines in the US and price increases for some older generic drugs.
Read said the pharmaceutical industry has been unfairly singled out amid claims that US healthcare costs are too high, pointing to charges by hospitals and outpatient services as primary culprits.
US drug prices on average rose only 2.8 percent in 2015, he said, after discounts and rebates to payers.
The Pfizer CEO applauded Trump’s call to speed up drug approvals.
“To the extent that they can remove regulations and make it easier and faster to bring drugs to market, that will make the market more competitive and bring down drug prices,” Read said.
As to Trump’s clarion call to bring manufacturing and jobs back to the US from the multinational industry, Read said that will require tax reform.
An accountant by trade, Read has been an outspoken critic of US corporate tax rates that he feels put Pfizer at a competitive disadvantage to overseas rivals.
He twice tried and failed to acquire large European-based companies that would have allowed New York-based Pfizer to relocate and take advantage of lower taxes.
“I’m very encouraged by the president’s affirmation that tax reform is one of his major priorities,” Read said. “Taxes have consequences.”
Earlier on Tuesday, Pfizer forecast adjusted profit for this year of US$2.5 to US$2.6 per share on revenue of US$52 billion to US$54 billion, in line with Wall Street estimates, according to Thomson Reuters I/B/E/S.
It reported adjusted fourth-quarter profit of US$0.47 per share, missing the average analysts’ estimate by US$0.03 as sales of its Prevnar pneumonia vaccine fell 23 percent to US$1.42 billion.
Pfizer said it expects Prevnar sales this year to be flat to slightly down.
Pfizer shares were up 0.7 percent at US$31.53 on Tuesday afternoon.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day